Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients
2016-001628-72Phase 2Completed
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, methotrexate, cytarabine, thiotepa and busulfan in primary central nervous system lymphoma (PCNSL), sponsored by Universitätsklinikum Freiburg. Primary endpoint: 1-year progression-free survival. Started Apr 2017; status: completed.
02
Drugs
rituximabmethotrexatecytarabinethiotepabusulfan
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on 2016-001628-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001628-72.